A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

NCT03246347 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer
Prostate Adenocarcinoma

Interventions

DRUG: ADT+Docetaxel+Enzalutamide

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]
[object Object]